Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia

Li,Yinghua; Yang,Lin; Pan,Yuxia; Yang,Jingci; Shang,Yintao; Luo,Jianmin

doi:10.3892/or.2014.3098

Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia

Authors:
- Yinghua Li
- Lin Yang
- Yuxia Pan
- Jingci Yang
- Yintao Shang
- Jianmin Luo
View Affiliations

Affiliations: Department of Hematology, The Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang, Hebei 050000, P.R. China
Published online on: March 19, 2014 https://doi.org/10.3892/or.2014.3098
Pages: 2438-2446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the unprecedented success of tyrosine kinase inhibitors (TKIs) in treating chronic myelogenous leukemia (CML), some patients nevertheless progress to advanced stages of the disease. Thus far, the biological basis leading to CML progression remains poorly understood. SH2-containing tyrosine phosphatase 1 (SHP-1) is reported to bind to p210BCR‑ABL1 and to function as a tumor suppressor. Furthermore, its substrates have been found to be essential for p210BCR-ABL1 leukemogenesis or CML progression. In the present study, we found that SHP-1 mRNA and protein levels were markedly decreased in patients in the accelerated and blastic phases of CML (AP-CML and BP-CML) compared to those in the chronic phase (CP-CML). In vitro, we demonstrated that overexpression of SHP-1 reduced p210BCR-ABL1 protein expression and activity in the K562 CML cell line and negatively regulated the AKT, MAPK, MYC and JAK2/STAT5 signaling pathways. Moreover, using a methylation-specific polymerase chain reaction (MSP) assay, abnormal methylation of the SHP-1 gene promoter region was found both in K562 cells and bone marrow (BM) or peripheral blood (PB) cells from AP-CML and BP-CML patients. In conclusion, our findings suggest that decreased expression levels of SHP-1 caused by aberrant promoter hypermethylation may play a key role in the progression of CML by dysregulating BCR-ABL1, AKT, MAPK, MYC and JAK2/STAT5 signaling.

View Figures

View References

1	Shtivelman E, Lifshitz B, Gale R and Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:550–554. 1985. View Article : Google Scholar : PubMed/NCBI
2	Ben-Neriah Y, Daley G, Mes-Masson A, Witte O and Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the BCR/ABL hybrid gene. Science. 233:212–214. 1986. View Article : Google Scholar : PubMed/NCBI
3	Quintas-Cardama A and Cortes J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 113:1619–1630. 2009.
4	Baccarani M, Deininger MW, Rosti G, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122:872–884. 2013. View Article : Google Scholar : PubMed/NCBI
5	Nash I: Chronic myeloid leukemia. N Engl J Med. 341:7651999. View Article : Google Scholar : PubMed/NCBI
6	Perrotti D, Jamieson C, Goldman J and Skorski T: Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 120:2254–2264. 2010. View Article : Google Scholar : PubMed/NCBI
7	Chen Y, Peng C, Li D and Li S: Molecular and cellular bases of chronic myeloid leukemia. Protein Cell. 1:124–132. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rumpold H and Webersinke G: Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL? Curr Cancer Drug Targets. 11:3–19. 2011. View Article : Google Scholar : PubMed/NCBI
9	Radich JP, Dai H, Mao M, et al: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 103:2794–2799. 2006. View Article : Google Scholar : PubMed/NCBI
10	Feng G, Hui C and Pawson T: SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science. 259:1607–1611. 1993. View Article : Google Scholar : PubMed/NCBI
11	Lorenz U: SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev. 228:342–359. 2009. View Article : Google Scholar : PubMed/NCBI
12	Li J, Xue L, Hao H, Han Y, Yang J and Luo J: Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Oncol Rep. 27:461–466. 2012.PubMed/NCBI
13	Dong Q, Siminovitch KA, Fialkow L, Fukushima T and Downey GP: Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. J Immunol. 162:3220–3230. 1999.PubMed/NCBI
14	Tapley P, Shevde N, Schweitzer P, et al: Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp Hematol. 25:122–131. 1997.PubMed/NCBI
15	Oka T, Ouchida M, Koyama M, et al: Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62:6390–6394. 2002.PubMed/NCBI
16	Chim CS, Fung TK, Cheung WC, Liang R and Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 103:4630–4635. 2004. View Article : Google Scholar
17	Zhang Q, Raghunath P, Vonderheid E, Odum N and Wasik M: Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 157:1137–1146. 2000. View Article : Google Scholar : PubMed/NCBI
18	Esposito N, Colavita I, Quintarelli C, et al: SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood. 118:3634–3644. 2011. View Article : Google Scholar
19	Bruecher-Encke B, Griffin J, Neel B and Lorenz U: Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia. 15:1424–1432. 2001. View Article : Google Scholar : PubMed/NCBI
20	Kharbanda S, Bharti A, Pei D, et al: The stress response to ionizing radiation involoves c-Abl-dependent phosphorylation of SHPTP1. Proc Natl Acad Sci USA. 93:6898–6901. 1996. View Article : Google Scholar : PubMed/NCBI
21	Hamilton A, Elrick L, Myssina S, et al: BCR-ABL activity and its response to drugs can be determined in CD34⁺ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia. 20:1035–1039. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lucas C, Harris R, Giannoudis A, Knight K, Watmough S and Clark R: BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. Br J Haematol. 149:458–460. 2010. View Article : Google Scholar : PubMed/NCBI
23	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
24	Khoury H, Kukreja M, Goldman J, et al: Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 47:810–816. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chong Z and Maiese K: The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 22:1251–1267. 2007.PubMed/NCBI
26	Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283. 2004. View Article : Google Scholar : PubMed/NCBI
27	Warsch W, Kollmann K, Eckelhart E, et al: High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 117:3409–3420. 2011. View Article : Google Scholar : PubMed/NCBI
28	Xie S, Wang Y, Liu J, et al: Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 20:6188–6195. 2001. View Article : Google Scholar : PubMed/NCBI
29	Samanta AK, Lin H, Sun T, Kantarjian H and Arlinghaus RB: Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66:6468–6472. 2006. View Article : Google Scholar : PubMed/NCBI
30	Samanta A, Chakraborty S, Wang Y, et al: Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 28:1669–1681. 2009. View Article : Google Scholar : PubMed/NCBI
31	Samanta A, Perazzona B, Chakraborty S, et al: Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 25:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
32	Luo J, Liu Z, Hao H, Wang F, Dong Z and Ryuzo O: Mutation analysis of hematopoietic cell phosphatase gene in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 12:128–132. 2004.(In Chinese).
33	Amin H, Hoshino K, Yang H, Lin Q, Lai R and Garcia-Manero G: Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol. 212:402–410. 2007. View Article : Google Scholar : PubMed/NCBI
34	Chim CS, Liang R, Leung MH and Kwong YL: Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol. 60:104–106. 2007. View Article : Google Scholar : PubMed/NCBI
35	Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T and Wasik MA: STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA. 102:6948–6953. 2005. View Article : Google Scholar : PubMed/NCBI
36	Han Y, Amin HM, Franko B, Frantz C, Shi X and Lai R: Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK⁺ anaplastic large-cell lymphoma. Blood. 108:2796–2803. 2006. View Article : Google Scholar : PubMed/NCBI
37	Neviani P, Santhanam R, Trotta R, et al: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8:355–368. 2005. View Article : Google Scholar : PubMed/NCBI
38	Wu C, Sun M, Liu L and Zhou G: The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
39	Radich JP: The biology of CML blast crisis. Hematology. 2007:384–391. 2007. View Article : Google Scholar